ACT of autologous CD8+ MHC class I restricted T cells specific for a HLA-A*24:02-restricted MCPyV LT-Ag92-101 TAg epitope mediated regressions of VP-MCC (13) and this tetramer approach is now in early clinical trials to treat VP-MCC (NCT01758458). The gene discussed is CD8A; the disease is Merkel cell skin cancer.